A1C Reduction with Semaglutide & Tirzepatide: What the Clinical Data Shows

Why A1C Is the Gold Standard for Measuring GLP-1 Success

When clinicians assess how well a metabolic medication is working, hemoglobin A1C (HbA1c) is the measurement they reach for first. Unlike a fasting glucose test that captures a single snapshot, A1C reflects the average blood sugar level across the previous 90–120 days by measuring the percentage of red blood cells carrying glucose molecules. It is harder to manipulate with a single day of healthy eating, and it correlates directly with long-term risks of cardiovascular disease, kidney disease, neuropathy, and retinopathy.

For anyone on GLP-1 receptor agonist therapy such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), A1C becomes a key report card. These medications do not merely suppress appetite. They actively mimic incretin hormones that regulate insulin secretion, suppress glucagon, slow gastric emptying, and improve peripheral insulin sensitivity. The result is a sustained, measurable improvement in glycemic control that A1C captures beautifully.

This guide draws on published data from the STEP clinical trial program for semaglutide and the SURPASS program for tirzepatide to give you exact numbers, timelines, and context. Whether you are managing type 2 diabetes, reversing prediabetes, or simply tracking metabolic health alongside weight loss, the data below tells a compelling story.

A1C Diagnostic Categories (ADA Guidelines)

Normal: Below 5.7%
Prediabetes: 5.7% – 6.4%
Diabetes: 6.5% or higher
Well-controlled diabetes target: Below 7.0%
Tighter target for motivated patients: Below 6.5%

Semaglutide A1C Data: What the STEP Trials Show

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program was a landmark series of Phase 3 trials evaluating semaglutide 2.4 mg once weekly for weight management. STEP 1 enrolled adults with obesity but without diabetes. STEP 2 enrolled adults with both overweight/obesity and type 2 diabetes, making it the most relevant trial for glycemic outcomes.

STEP 2: Semaglutide in Type 2 Diabetes

In STEP 2, adults with type 2 diabetes and a mean baseline A1C of approximately 8.1% were randomized to semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo. After 68 weeks, the primary glycemic results were:

Semaglutide 2.4 mg: Mean A1C reduction of 1.6 percentage points (from ~8.1% to ~6.5%)
Semaglutide 1.0 mg: Mean A1C reduction of approximately 1.5 percentage points
Placebo: A1C reduction of approximately 0.4 percentage points
68% of semaglutide 2.4 mg patients achieved A1C below 7.0%

Notably, the 2.4 mg dose produced greater weight loss than the 1.0 mg dose (9.6% vs 7.0% body weight), and this additional weight loss likely contributed to greater insulin sensitivity improvements.

STEP 1 and STEP 5: Non-Diabetic Patients

STEP 1 enrolled adults without diabetes with a baseline mean A1C of approximately 5.6%. Despite having normal-range baseline A1C, the trial still reported meaningful metabolic changes:

Mean A1C reduction of approximately 0.4 percentage points versus 0.1 points on placebo
Patients with prediabetes at baseline were much more likely to return to normal A1C range
Fasting insulin levels fell significantly, reflecting improved insulin sensitivity

STEP 5, the 2-year extension trial, confirmed that these A1C improvements were sustained at 104 weeks, not just the initial 68-week endpoint.

Key Semaglutide A1C Summary (STEP Program)

Diabetic patients: mean -1.5% to -1.6% A1C reduction at 68 weeks on 2.4 mg. Non-diabetic/prediabetic patients: -0.3% to -0.7% depending on baseline, with many returning to normal range.

These numbers matter beyond their statistical significance. An A1C reduction from 8.1% to 6.5% takes a patient from poorly controlled diabetes to the ADA-recommended target in a single medication without adding additional glucose-lowering agents. For patients and clinicians considering what to expect from A1C on GLP-1, these real-world anchors are far more useful than general claims about blood sugar improvement.

Tirzepatide A1C Data: What the SURPASS Trials Show

Tirzepatide is a dual GIP/GLP-1 receptor agonist, the first of its kind approved for both type 2 diabetes (Mounjaro) and obesity (Zepbound). The SURPASS clinical trial program enrolled thousands of adults with type 2 diabetes across five major trials, generating the most detailed glycemic dataset of any GLP-1 class medication to date.

SURPASS-1: Tirzepatide Monotherapy

SURPASS-1 evaluated tirzepatide as standalone therapy in patients with type 2 diabetes not controlled on diet and exercise alone. Baseline A1C averaged 7.9%. After 40 weeks:

Tirzepatide 5 mg: A1C reduction of 1.87 percentage points
Tirzepatide 10 mg: A1C reduction of 1.89 percentage points
Tirzepatide 15 mg: A1C reduction of 2.07 percentage points
87–92% of patients achieved A1C below 7.0% across dose groups
31–52% achieved A1C below 5.7% (normal range) across dose groups

SURPASS-2: Direct Head-to-Head vs. Semaglutide

SURPASS-2 is the pivotal trial for comparing tirzepatide and semaglutide on glycemic outcomes. It enrolled 1,879 adults with type 2 diabetes with baseline A1C of approximately 8.3%. Patients received tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg for 40 weeks. Results:

Tirzepatide 5 mg: A1C reduction of 2.01 points vs. semaglutide's 1.86 points
Tirzepatide 10 mg: A1C reduction of 2.24 points
Tirzepatide 15 mg: A1C reduction of 2.30 points (vs. 1.86 for semaglutide 1 mg)
All tirzepatide doses significantly outperformed semaglutide 1 mg on A1C (p<0.001)
At 15 mg: 92% achieved A1C <7.0%, compared to 81% on semaglutide 1 mg

This trial confirmed tirzepatide's glycemic advantage over semaglutide at equivalent doses. It is important to note that SURPASS-2 used semaglutide 1 mg rather than the 2.4 mg weight-loss dose used in STEP trials, making exact cross-trial comparison imperfect.

SURPASS-5: Combination with Insulin

SURPASS-5 evaluated adding tirzepatide to basal insulin in inadequately controlled type 2 diabetes. Starting A1C averaged 8.3%. After 40 weeks:

Tirzepatide 15 mg: mean A1C reduction of 2.11 percentage points
Placebo: A1C reduction of only 0.86 points
68% of tirzepatide 15 mg patients achieved A1C below 7.0%

Key Tirzepatide A1C Summary (SURPASS Program)

Diabetic patients: mean -2.1% to -2.3% A1C reduction at 15 mg dose across SURPASS trials. Up to 92% of patients achieved A1C <7.0%, and up to 52% achieved normal A1C (<5.7%) at the highest dose.

Semaglutide vs. Tirzepatide for Glycemic Control: A Direct Comparison

Based on available trial data, tirzepatide demonstrates a measurable advantage in A1C reduction compared to semaglutide. Here is a structured side-by-side summary:

Metric	Semaglutide (STEP)	Tirzepatide (SURPASS)
Mean A1C reduction (diabetic)	~1.5% (2.4 mg dose)	~2.1% (15 mg dose)
% achieving A1C <7.0%	68% (STEP 2, 2.4 mg)	92% (SURPASS-2, 15 mg)
% achieving normal A1C (<5.7%)	~10–20% (estimated)	31–52% (dose-dependent)
A1C reduction vs. each other	Reference	~0.5 points greater (SURPASS-2)
Mechanism advantage for glycemia	GLP-1 receptor agonism	Dual GLP-1 + GIP agonism

The tirzepatide advantage likely stems from GIP receptor co-activation. GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 to amplify insulin secretion, and GIP receptor signaling may also improve pancreatic beta cell mass and function over time. This creates a dual pathway for blood sugar reduction that semaglutide alone cannot replicate.

That said, both medications are dramatically effective compared to placebo and to most alternative diabetes medications. Patients who need greater than 2-point A1C reductions or who have failed semaglutide therapy may find tirzepatide a meaningful upgrade. For patients with prediabetes or modest diabetes, semaglutide remains highly effective and may be the appropriate first-line choice depending on cost, availability, and individual response.

For a deeper clinical comparison, see our full guide on semaglutide vs. tirzepatide, which covers weight loss, cardiovascular outcomes, side effects, and cost alongside glycemic data.

Timeline of A1C Improvement on GLP-1 Therapy

Understanding when A1C improvements occur helps patients set realistic expectations and interpret their lab results correctly. The timeline follows a predictable pattern driven by the biological constraints of how A1C is formed.

Days 1–14: Immediate Glucose Lowering

GLP-1 medications begin working on the very first dose. Fasting glucose drops within 24–48 hours as glucagon suppression reduces hepatic glucose output. Post-meal glucose spikes flatten due to slowed gastric emptying and enhanced insulin secretion. Patients using a continuous glucose monitor (CGM) can observe these changes almost immediately. This early period is critically important because it establishes the favorable glucose environment that will eventually appear in A1C.

Weeks 4–8: Dose Escalation Window

Most GLP-1 protocols begin at lower starter doses and titrate up every 4 weeks to minimize GI side effects. During this period, glucose improvements are real but partial, as the therapeutic dose has not been reached. Patients should not draw conclusions about long-term A1C response during the titration phase. The full glycemic effect requires reaching and maintaining the target maintenance dose.

Month 3: First Meaningful A1C Check

The 3-month mark is when A1C begins reflecting a meaningful portion of time on therapy. Because red blood cells live 90–120 days, the first 3-month A1C blends the pre-treatment period with the treatment period. Expect to see 40–60% of your eventual A1C reduction by this check. Diabetic patients who started at A1C 8.0–9.0% should expect values approaching 7.0–7.5% if on therapeutic dose. This is the standard time for a Trimi provider check-in and lab review.

Month 6: Near-Maximum A1C Benefit

By 6 months, patients have been on therapeutic doses long enough for the full 90-day reflection window to be entirely on-treatment. The combined effect of direct glycemic action plus weight-loss-driven insulin sensitivity improvement is now fully expressed. The 6-month A1C typically reflects 85–95% of the final reduction the medication will produce. Most STEP and SURPASS trials used a primary endpoint at 40–68 weeks, which captures this plateau.

Month 12 and Beyond: Sustained Maintenance

Long-term trial data (STEP 5 at 2 years, SURPASS extensions) shows that A1C improvements are maintained with continued therapy. Patients who lose additional weight after the 6-month mark may see modest further A1C reductions. Critically, trials that tested discontinuation (such as the STEP 4 withdrawal trial) showed that stopping GLP-1 medication led to A1C reverting toward baseline within 12–20 weeks, underscoring the importance of ongoing treatment. Learn about how GLP-1 therapy works long-term to understand the maintenance phase.

Who Benefits Most from GLP-1 A1C Reduction?

GLP-1 medications improve A1C across a broad spectrum of patients, but certain profiles consistently show the greatest glycemic benefit.

Patients with Type 2 Diabetes and High Baseline A1C

The most dramatic absolute A1C reductions occur in patients with the highest starting values. A patient with an A1C of 9.5% has far more room for improvement than one at 6.8%, and trials consistently demonstrate this correlation. For patients where oral diabetes medications are insufficient, GLP-1 therapy can achieve target A1C without the hypoglycemia risk of insulin or sulfonylureas. Trimi's clinical team routinely evaluates GLP-1 candidates for type 2 diabetes management as a primary indication.

Prediabetes Patients Seeking Prevention

One of the most underappreciated benefits of GLP-1 therapy is prediabetes reversal. Approximately 38% of American adults have prediabetes (A1C 5.7–6.4%), and without intervention, 15–30% will develop type 2 diabetes within 5 years. GLP-1 medications attack prediabetes through multiple simultaneous mechanisms: direct glycemic control, significant weight loss, and improvements in insulin sensitivity. In analyses from STEP trials, patients with prediabetes who completed treatment had a 73% lower rate of progression to type 2 diabetes compared to placebo. This represents one of the most powerful diabetes prevention tools available.

Obese Patients with Insulin Resistance

Even patients with normal A1C who have insulin resistance (often detectable via elevated fasting insulin or HOMA-IR) benefit from GLP-1 therapy's metabolic effects. Weight loss alone improves insulin sensitivity significantly, but the direct GLP-1 receptor effects amplify this benefit. Patients in this category may see smaller A1C changes (since there is less room to fall) but will experience meaningful improvements in insulin area under the curve and reduced future diabetes risk.

Patients with Obesity and Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is closely linked to insulin resistance and elevated A1C. GLP-1 therapy addresses both conditions simultaneously: reducing hepatic fat content, lowering ALT, and improving insulin signaling in the liver. As liver metabolic function improves, this feeds back positively into A1C reduction, making patients with NAFLD particularly good responders to glycemic therapy.

A1C Monitoring Recommendations on GLP-1 Therapy

Effective monitoring requires knowing which tests to order, when to order them, and how to interpret the results in the context of treatment. Trimi uses a structured monitoring protocol based on clinical guidelines and trial evidence.

Baseline Testing (Before Starting Medication)

A1C: Establishes your starting point. Required to interpret future changes.
Fasting glucose: Paired with A1C to confirm prediabetes or diabetes diagnosis.
Fasting insulin and HOMA-IR: Quantifies degree of insulin resistance. Higher values predict greater A1C response to GLP-1 therapy.
Comprehensive metabolic panel: Establishes kidney and liver baseline, both of which affect drug metabolism and metabolic improvement tracking.
Lipid panel: Elevated triglycerides and low HDL are common in patients with poor glycemic control and typically improve alongside A1C.

Follow-Up Testing Schedule

3 months: First A1C recheck. Assess partial response, confirm dose is appropriate, identify patients needing dose escalation.
6 months: Full A1C assessment. Compare to baseline. Evaluate whether target A1C has been reached. Adjust concurrent diabetes medications if necessary.
12 months: Annual comprehensive panel. Confirm A1C maintenance, assess cardiovascular risk markers, review overall metabolic health.
Ongoing (diabetic patients): Every 3 months if A1C is above target; every 6 months once at goal.

For patients managing type 2 diabetes alongside GLP-1 therapy, reviewing the full blood test monitoring protocol ensures no key metabolic markers are missed. Trimi's providers review labs with patients at each check-in visit and adjust treatment plans based on objective data, not just weight loss metrics.

Warning: Medication Interactions in Diabetic Patients

As A1C improves on GLP-1 therapy, patients who also take insulin, sulfonylureas (glipizide, glimepiride), or meglitinides may develop hypoglycemia if their other medications are not adjusted downward. Do not reduce or stop concurrent diabetes medications without provider guidance. Trimi proactively reviews and adjusts combination therapy as glycemic targets are reached.

GLP-1 Therapy and Prediabetes: Preventing the Progression

The medical community has long struggled with effective prediabetes interventions. Lifestyle modification programs reduce diabetes progression by 58% in trial settings but are notoriously difficult to sustain in real-world practice. Metformin reduces progression by approximately 31%. GLP-1 therapy is emerging as the most powerful pharmacological tool for prediabetes prevention, combining direct glycemic effects with substantial, maintained weight loss.

The SELECT trial (semaglutide for cardiovascular outcomes in obesity without diabetes) provided revealing secondary data on prediabetes. Among participants with prediabetes at baseline, semaglutide treatment led to a 73% reduction in new-onset type 2 diabetes over the 3.3-year trial period. This is not a small effect — it represents a near elimination of diabetes progression risk in a high-risk obese population.

For patients identified as prediabetic at baseline A1C testing, GLP-1 therapy offers a dual benefit: the primary weight management goal they enrolled for plus a powerful diabetes prevention benefit that addresses one of the most significant long-term health risks they face. This is why Trimi includes A1C testing as standard, not optional, at baseline. See our guide on blood tests before starting GLP-1 to understand the full pre-treatment workup.

Trimi's A1C-Focused Approach to GLP-1 Treatment

At Trimi, glycemic health is treated as a core metric of treatment success alongside weight loss, not an afterthought reserved for diabetic patients. Our clinical protocol reflects the evidence base reviewed in this guide:

Mandatory baseline A1C for all patients: We test A1C before starting any patient on semaglutide or tirzepatide, regardless of whether they have a diabetes diagnosis. This establishes a metabolic baseline and frequently identifies prediabetes that was previously unknown.
Individualized medication selection: Patients with type 2 diabetes or A1C above 7.0% are evaluated for tirzepatide as the preferred medication given its superior glycemic efficacy demonstrated in SURPASS trials. Patients without diabetes are typically appropriate for either agent based on their overall profile and preference.
Structured 3- and 6-month lab reviews: Our standard protocol includes A1C testing at 3 months (first check-in) and 6 months (comprehensive review). Results are reviewed with patients and used to guide dose optimization and concurrent medication adjustments.
CGM integration for qualifying patients: Patients with type 2 diabetes or elevated prediabetes baseline are offered CGM guidance to track real-time glucose responses alongside quarterly A1C data, providing a more complete glycemic picture.
Concurrent medication coordination: Our providers work with patients' primary care physicians and endocrinologists to safely reduce or discontinue concurrent diabetes medications as A1C targets are reached, preventing medication overload and hypoglycemia risk.

If you are evaluating GLP-1 therapy for weight loss and want to understand what metabolic monitoring comes with the program, start your Trimi assessment today to see the full clinical protocol. For patients who are on existing medications and want to understand how GLP-1 therapy fits in, our providers conduct thorough medication reviews as part of onboarding.

Patients already using GLP-1 medications elsewhere who want to compare their current monitoring protocol to evidence-based standards can review our guide to evaluating GLP-1 providers.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. A1C results should always be interpreted by a qualified healthcare provider in the context of your complete medical history, current medications, and individual health goals. Clinical trial results represent population averages; individual responses will vary. Do not adjust diabetes medications based on this information or on A1C results alone without consulting your provider.

Frequently Asked Questions

How much does semaglutide lower A1C according to clinical trials?

The STEP clinical trial program showed semaglutide at 2.4 mg reduced A1C by approximately 1.5 percentage points in patients with type 2 diabetes and obesity. Earlier SUSTAIN trials in purely diabetic populations showed reductions of 1.0–1.8 points depending on dose and baseline A1C. Non-diabetic patients with prediabetes see more modest reductions of 0.3–0.7 points, while those with normal baseline A1C see minimal change.

How much does tirzepatide lower A1C in the SURPASS trials?

The SURPASS trial program demonstrated tirzepatide at 15 mg reduced A1C by a mean of 2.1–2.3 percentage points in type 2 diabetes patients. In SURPASS-2, which compared tirzepatide directly to semaglutide 1 mg, tirzepatide 15 mg outperformed semaglutide by approximately 0.5 percentage points on A1C reduction. Up to 97% of tirzepatide-treated patients achieved an A1C below 7.0%, and many reached completely normal glycemic levels below 5.7%.

Is tirzepatide better than semaglutide for A1C reduction?

Head-to-head data from SURPASS-2 shows tirzepatide produces greater A1C reductions than semaglutide 1 mg at equivalent treatment periods. At the 15 mg dose, tirzepatide reduces A1C by roughly 0.5 percentage points more than semaglutide 1 mg. However, this comparison used semaglutide 1 mg rather than the 2.4 mg weight-loss dose. Both medications are highly effective for glycemic control, and the best choice depends on your full clinical picture, not A1C alone.

How long does it take for A1C to improve on GLP-1 medication?

A1C reflects a 90-day rolling average, so meaningful changes require at least 3 months of treatment. Patients typically see day-to-day fasting glucose improvements within the first 1–2 weeks, but these will not appear in A1C until after the 90-day window. The first A1C check should be at 3 months, where most patients see 50–70% of their eventual total reduction. Full benefit is usually apparent by the 6-month mark.

Can GLP-1 medications reverse prediabetes?

Clinical evidence strongly suggests GLP-1 therapy can reverse prediabetes. In the STEP 5 trial and related analyses, patients with prediabetes starting A1C (5.7–6.4%) saw an average reduction of 0.3–0.6 points, with many returning to normal A1C range. Additionally, data from the semaglutide SELECT trial showed semaglutide reduced progression from prediabetes to type 2 diabetes. Sustained treatment is needed to maintain these benefits, as A1C tends to drift back toward baseline after discontinuation.

Do I need to monitor A1C if I do not have diabetes?

Yes. Baseline and follow-up A1C testing is recommended for all GLP-1 patients, regardless of diabetes status. A baseline test may reveal undiagnosed prediabetes in up to 38% of overweight adults. Follow-up testing confirms metabolic improvement, helps titrate treatment, and provides objective evidence of insulin sensitivity gains that complement weight loss. Trimi includes A1C monitoring as a standard part of its treatment protocol.

What factors most influence how much A1C drops on semaglutide or tirzepatide?

The key factors are starting A1C level (higher baseline means more room for reduction), medication dose (higher doses produce larger reductions), degree of weight loss achieved (every 1% of body weight lost improves insulin sensitivity), diet quality (low-glycemic eating amplifies medication effects), exercise habits, and remaining pancreatic beta cell function in patients with longstanding diabetes. Individual genetics and gut microbiome composition also play a role that is still being researched.

Start Your A1C-Monitored GLP-1 Program

Trimi's clinical protocol includes baseline and follow-up A1C testing for every patient, so you can track exactly how your metabolic health is improving alongside weight loss.

Get Your Assessment

More on Health Conditions

A1C on GLP-1: What to Expect

Blood Tests to Monitor on GLP-1

Semaglutide vs Tirzepatide: Full Comparison